| 08.18.21 | Merz targets Botox with needleless delivery pact; Sydnexis bags cash to treat short-sightedness

Laden...

3 jaren geleden

Html
Tekst

Aptar lands option on high payload inhaler To view this email as a web page, click here

Webinar: Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms

Join this webinar to hear experts share methods that can help evaluate whether a molecule is suitable for controlled release applications. Register Today.

Today's Rundown

Beating Botox: Merz and Vensica team up for needleless delivery Sydnexis scoops $45M to treat short-sightedness in kids Aptar's active deal team strikes again, bagging option on high payload dry powder inhaler Nanoparticles get drugs into the brain to clear HIV reservoirs Baxter's preprogrammed infusion pump software recall lands FDA Class I label

Featured Story

Beating Botox: Merz and Vensica team up for needleless delivery

By Nick Paul Taylor

Merz Therapeutics has opened another front in its effort to win market share from Botox. Spying a chance to differentiate itself through delivery in overactive bladder, Merz has partnered with Vensica Therapeutics for the needleless administration of its challenger to the blockbuster neurotoxin.

Webinar: Effective Scale-Up and Technology Transfer Strategies for Spray Dried Amorphous Dispersions

Wednesday, September 8 | 11am ET / 8am PT

Attend this webinar to learn from real world case studies about best practices and strategies to mitigate risks and ensure a successful tech transfer from development through to commercial scale spray drying of pharmaceutical products. Learn More.

Sydnexis scoops $45M to treat short-sightedness in kids

By Nick Paul Taylor

The race to treat nearsightedness in kids with low-dose atropine eye drops is heating up. Sydnexis is the latest company to make waves in the space, reeling in $45 million to fund phase 3 and selling the European rights to its candidate.

Aptar's active deal team strikes again, bagging option on high payload dry powder inhaler

By Nick Paul Taylor

The flurry of business development activity at Aptar continues. Having made moves for injectable drug delivery and digital therapeutic players in recent weeks, Aptar has now nabbed an option on a high payload dry powder inhaler.

Nanoparticles get drugs into the brain to clear HIV reservoirs

By Nick Paul Taylor

The brain is one of the final hiding places of HIV from combination antiretroviral therapy. Modern treatments effectively suppress levels of the virus in most parts of the body but struggle to cross the blood-brain barrier, allowing reservoirs to form in the central nervous system. The need to wipe out the reservoirs has spurred research into nanoparticles capable of entering the brain.

Baxter's preprogrammed infusion pump software recall lands FDA Class I label

By Andrea Park

Baxter initiated the recall in July after a defect was discovered in its Dose IQ safety software, which could potentially cause it to transmit incorrect drug dosing information to Spectrum IQ infusion pumps.